NEWS
Notification of receipt of response regarding Pre -IND meeting with the US FDA
Tregem Biopharmaceuticals Inc. (Kyoto City, President and CEO: Honoka Kiso; hereinafter referred to as "Tregem") has been holding pre-IND meetings with the U.S. Food and Drug Administration (FDA) for the U.S. development of an antibody drug (development code: TRG-035) for congenital tooth agenesis.We are pleased to announce that we have now received an official response […]
Toregem’s Anti-USAG-1 Antibody “TRG035” Designated as an Orphan Drug by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Severe Congenital Oligodontia
Toregem BioPharma Co., Ltd. (Head Office: Kyoto City; CEO: Honoka Kiso; hereinafter referred to as Toregem)’s investigational anti-USAG-1 antibody 'TRG035” has been designated by the Ministry of Health, Labour and Welfare as an orphan drug for the target disease “severe congenital hypodontia”.20250929_TRG035_Severe_Congenital_Partial_Anodontia_Orphan_Drug_Japan.pdf
We are going to exhibit at BioJapan 2025, which will be held from October 8th to 10th, 2025.
We are pleased to announce that we will have a booth at BioJapan2025, one of Asia's largest partnering events in the life science field.(Booth number: D-119)This event will be held at Pacifico Yokohama from October 8 (Wed.) to 10 (Fri.). For more information, please visithttps://jcd-expo.jp/ja/
We will be exhibiting at the Global Startup EXPO 2025
We are pleased to announce that we have been selected to participate in the ‘Global Startup EXPO 2025’, where deep tech startups from around the world will gather, and will be exhibiting at a booth within the Osaka-Kansai Expo site. [Event Overview (from the Ministry of Economy, Trade and Industry release)]Name: Global Startup EXPO 2025 […]
We have been selected for the Nakanoshima Qross Drug Discovery and Commercialisation Promotion Programme Support Project.
We are pleased to announce that we have been selected for the Nakanoshima Qross Drug Discovery and Commercialisation Promotion Programme Support Project. This initiative aims to rebuild and strengthen Japan's drug discovery capabilities by establishing a new, end-to-end support system specifically designed to commercialise drug discovery seeds held by startups and academia. This addresses challenges […]